Reversible Lysine Specific Demethylase 1 (LSD1) Inhibitors: A Promising Wrench to Impair LSD1

• Published in: Journal of medicinal chemistry Vol. 64; no. 5; pp. 2466 - 2488
• Main Authors: Dai, Xing-Jie, Liu, Ying, Xue, Lei-Peng, Xiong, Xiao-Peng, Zhou, Ying, Zheng, Yi-Chao, Liu, Hong-Min
• Format: Journal Article
• Language: English
• Published: United States American Chemical Society 11.03.2021
• ISSN: 0022-2623; 1520-4804
• DOI: 10.1021/acs.jmedchem.0c02176

As a flavin adenine dinucleotide (FAD)-dependent monoamine oxidase, lysine specific demethylase 1 (LSD1/KDM1A) functions as a transcription coactivator or corepressor to regulate the methylation of histone 3 lysine 4 and 9 (H3K4/9), and it has emerged as a promising epigenetic target for anticancer treatment. To date, numerous inhibitors targeting LSD1 have been developed, some of which are undergoing clinical trials for cancer therapy. Although only two reversible LSD1 inhibitors CC-90011 and SP-2577 are in the clinical stage, the past decade has seen remarkable advances in the development of reversible LSD1 inhibitors. Herein, we provide a comprehensive review about structures, biological evaluation, and structure–activity relationship (SAR) of reversible LSD1 inhibitors.